Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting

Area of Science:

• Ophthalmology
• Molecular Biology
• Vascular Biology

Background:

• Angiogenesis, the formation of new blood vessels, is crucial for tissue function but can cause disease when dysregulated.
• Neovascular eye diseases, such as macular degeneration, involve pathological angiogenesis.
• Current treatments like VEGF antagonists have limitations and off-target effects.

Purpose of the Study:

• To investigate the role of the Ras pathway in angiogenic sprouting.
• To explore microRNA-132 as a potential therapeutic target for neovascular eye diseases.
• To evaluate the efficacy of targeting microRNA-132 against VEGF antagonists.

Main Methods:

• Analysis of Ras pathway activity in developing and pathological vascular networks.
• Assessment of p120RasGAP expression in endothelial cells.
• Experimental delivery of microRNA-132 to mouse eyes.
• Comparison of microRNA-132 inhibition with VEGF antagonists in rodent models of ocular neovascularization.

Main Results:

• The Ras pathway is active in the growing vascular front.
• p120RasGAP, an endogenous Ras inhibitor, is downregulated in neovascular models.
• MicroRNA-132 negatively regulates p120RasGAP.
• α-miR-132 delivery disrupted tip cell Ras activity and prevented angiogenic sprouting.
• Targeting microRNA-132 was more potent than VEGF-trap in preventing ocular neovascularization.

Conclusions:

• MicroRNA-132 is a key regulator of angiogenic sprouting via the Ras pathway.
• Targeting microRNA-132 is a promising therapeutic strategy for neovascular eye diseases.
• This approach may prevent vision loss irrespective of the underlying neovascular stimulus.